



Adherium appoints Daniel Kaplon as Chief Financial Officer

Melbourne, Australia – 21 September 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the appointment of Mr Daniel Kaplon as Chief Financial Officer, effective 10 October 2022.

Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “we are very pleased to have attracted a candidate of Daniel’s calibre to Adherium. His strongly credentialed finance and healthcare industry background and his entrepreneurially driven commercial experience add important capabilities and assets to the leadership team directing our growth strategy.”

Daniel commented, “Joining Adherium at this exciting stage is a fantastic opportunity and I look forward to contributing to the team that is making a positive impact on patient lives and outcomes using leading respiratory digital technology.”

Daniel Kaplon will be based in Melbourne and report directly to Mr Legleiter.

About Daniel Kaplon

Mr Kaplon is a Chartered Accountant and established company executive with 25 years finance, operations and commercial experience having worked in ASX-listed and private entities in healthcare, health technology and manufacturing. Career highlights include Ramsay Health Care where Mr Kaplon was instrumental in setting up its pharmacy division and then leading the national adoption of electronic prescriptions as CFO/COO at MediSecure. He has an undergraduate honours degree in Commerce, business degree in Transport and Logistics Management, and a Master of Entrepreneurship and Innovation (MEI) during which he co-founded two medical device companies.

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and



patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com _

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor and Media Enquiries:

Hannah Howlett
WE Communications
WE-AUAdherium@we-worldwide.com